Stem Cell Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Stem Cell Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Stem Cell Transplantation
Stem cell transplant postremission improves high-risk acute lymphoblastic leukemia survival
August 14th, 2006
Allogeneic hematopoietic stem cell transplantation administered postremission improves the survival of adult patients with high-risk acute lymphoblastic leukemia. According to a study from Japan, "The prognosis for adult patients with acute lymphoblastic leukemia (ALL) remains unsatisfactory primarily because of the high incidence of recurrence. Therefore, optimal postremission therapy is a matter of vital concern. In particular, the clinical efficacy of allogeneic hematopoietic stem cell transplantation (HSCT) should be clarified." "Rigorous criteria were used to select 7 studies of adult ALL that prospectively assessed overall survival (OS) using...
Source: Stem Cell Week (2006-08-14)
|
